| 免疫治疗纠正脓毒症免疫麻痹的研究进展 |
| 投稿时间：2022-03-28 修订日期：2022-08-24 点此下载全文 |
| 引用本文：邢信昊,陈林林,凌忠毅,王彦.免疫治疗纠正脓毒症免疫麻痹的研究进展[J].药学实践杂志,2023,41(1):1~7,35 |
| 摘要点击次数: 779 |
| 全文下载次数: 2058 |
|
| 基金项目:国家自然科学基金（81772124）；上海市“科技创新行动计划”生物医药科技支撑专项（20S11902900） |
|
| 中文摘要:免疫麻痹是导致脓毒症中晚期患者死亡的主要原因，纠正免疫麻痹状态是脓毒症治疗的重要方向。在脓毒症的病理过程中，多种因素会导致细胞因子分泌失调，抗原提呈细胞功能减弱，淋巴细胞凋亡和耗竭，最终导致免疫麻痹、二次感染甚至患者死亡。对处于免疫麻痹状态的脓毒症患者，GM-CSF、IFN-γ、IL-7和IL-15等细胞因子，PD-1/PD-L1抗体、CTLA-4抗体、TIM-3抗体和LAG-3抗体等免疫检查点相关疗法，胸腺肽α1、免疫球蛋白等免疫活性物质都可能有利于纠正患者的免疫麻痹状态。本文对免疫治疗纠正脓毒症免疫麻痹的研究进展做一综述。 |
| 中文关键词:免疫治疗 脓毒症 免疫麻痹 细胞因子 免疫检查点 免疫活性物质 |
| |
| Research progress of immunotherapies on correction of immunoparalysis in sepsis |
|
|
| Abstract:Immunoparalysis is the main cause of death in patients with intermediate and terminal sepsis. The correction of immunoparalysis is an important direction of sepsis treatment. In the pathological process of sepsis, a variety of factors contribute to the imbalanced secretion of cytokines, weakened function of antigen-presenting cells, apoptosis and depletion of lymphocytes, and ultimately lead to immunoparalysis, secondary infection, and even patient deaths. Cytokines such as GM-CSF, IFN-γ, IL-7, and IL-15, immune checkpoint-related therapies such as PD-1/PD-L1 antibodies, CTLA-4 antibodies, TIM-3 antibodies, and LAG-3 antibodies, and immunoreactive substances such as thymosin α1 and immunoglobulin might be beneficial to correct the immune paralysis of patients. the progress of immunotherapy to correct immune paralysis in sepsis were reviewed in this article. |
| keywords:immunotherapy sepsis immunoparalysis cytokines immune checkpoint immunoreactive substances |
| 查看全文 查看/发表评论 下载PDF阅读器 |
|
| 关闭 |
|
|
|
